BRUKER CORPORATION

(BRKR)
  Report
Real-time Estimate Cboe BZX  -  05/23 09:54:38 am EDT
59.69 USD   -0.89%
05/16Bruker Board Declares Quarterly Dividend of $0.05 Per Common Share, Payable June 17 to Shareholders as of June 1
MT
05/16Bruker Announces Quarterly Dividend
BU
05/16Bruker Corporation Announces Quarterly Cash Dividend, Payable on June 17, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Bruker Announces $500 Million Private Placement of Senior Notes to Support Strategic Growth Objectives

12/08/2021 | 07:03am EDT

Bruker Corporation (Nasdaq: BRKR) announced today that it has completed a new private placement of 10-year senior notes in the aggregate principal amount of $500 million to enhance its financial flexibility and fund strategic growth objectives.

Gerald Herman, Bruker’s Executive Vice President & Chief Financial Officer, commented “This new debt financing capitalizes on the low interest rate environment in European capital markets, locks in attractive fixed rates for the next decade, and provides Bruker with significantly expanded capacity to continue investment in our Project Accelerate 2.0 initiatives and future strategic opportunities.”

Under private placement note terms, 300 million Swiss Franc 0.88% Series A senior notes and 150 million Euro 1.03% Series B senior notes due December 8, 2031, were issued and sold to a limited number of accredited institutional investors in an offering exempt from the registration requirements of the Securities Act of 1933, as amended.

Bruker intends to use proceeds from this financing for general corporate purposes, including the repayment of maturing debt obligations and to support strategic growth objectives.

The new financing arrangements are subject to customary affirmative and negative covenants and other terms as detailed in a filing with the Securities and Exchange Commission on Form 8-K, dated December 8, 2021.

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology. For more information, please visit: www.bruker.com.

Forward Looking Statements

Any statements contained in this press release which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the expected interest cost reduction associated with the financing arrangements. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, risks and uncertainties relating to adverse changes in conditions in the global economy and volatility in the capital markets, fluctuations in foreign currency exchange rates, our ability to successfully implement and execute on our capital management initiatives, our ability to maintain our leverage and interest coverage ratios required by the financing arrangements, our ability to make payments on our financial obligations when they become due, and other risk factors discussed from time to time in our filings with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2020. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.


© Business Wire 2021
All news about BRUKER CORPORATION
05/16Bruker Board Declares Quarterly Dividend of $0.05 Per Common Share, Payable June 17 to ..
MT
05/16Bruker Announces Quarterly Dividend
BU
05/16Bruker Corporation Announces Quarterly Cash Dividend, Payable on June 17, 2022
CI
05/10Bruker and TOFWERK Form Strategic Partnership in High-Speed, Ultra-Sensitive Solutions ..
BU
05/09Bruker Launches Novel 7 Tesla and 9.4 Tesla Preclinical MRI Magnets
BU
05/09Bruker Launches Novel 7 Tesla and 9.4 Tesla Preclinical MRI Magnets
CI
05/06BRUKER CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF..
AQ
05/05SVB Leerink Adjusts Bruker's Price Target to $87 from $85, Keeps Outperform Rating
MT
05/05Bruker Corporation acquired unknown minority stake in Tofwerk AG for CHF 18 million.
CI
05/04TRANSCRIPT : Bruker Corporation, Q1 2022 Earnings Call, May 04, 2022
CI
More news
Analyst Recommendations on BRUKER CORPORATION
More recommendations
Financials (USD)
Sales 2022 2 568 M - -
Net income 2022 300 M - -
Net Debt 2022 157 M - -
P/E ratio 2022 29,9x
Yield 2022 0,31%
Capitalization 8 988 M 8 988 M -
EV / Sales 2022 3,56x
EV / Sales 2023 3,30x
Nbr of Employees 7 765
Free-Float 57,8%
Chart BRUKER CORPORATION
Duration : Period :
Bruker Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRUKER CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 60,22 $
Average target price 75,63 $
Spread / Average Target 25,6%
EPS Revisions
Managers and Directors
Frank H. Laukien Chairman, President & Chief Executive Officer
Gerald N. Herman Chief Financial Officer & Executive Vice President
William Alderman Linton Lead Independent Director
Richard A. Packer Independent Director
Hermann Fritz Requardt Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BRUKER CORPORATION-28.23%8 988
THERMO FISHER SCIENTIFIC-16.80%217 320
DANAHER CORPORATION-23.47%180 262
INTUITIVE SURGICAL, INC.-39.03%78 637
SIEMENS HEALTHINEERS AG-16.99%64 649
EDWARDS LIFESCIENCES CORPORATION-27.19%58 644